Rabbit Recombinant Monoclonal Neuraminidase antibody. Suitable for WB and reacts with Human samples. Cited in 3 publications.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Flow Cyt | WB | |
---|---|---|
Human | Not recommended | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody. |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/2000 | Notes - |
Select an associated product type
Catalyzes the removal of sialic acid (N-acetylneuraminic acid) moieties from glycoproteins and glycolipids. To be active, it is strictly dependent on its presence in the multienzyme complex. Appears to have a preference for alpha 2-3 and alpha 2-6 sialyl linkage.
NANH, NEU1, Sialidase-1, Acetylneuraminyl hydrolase, G9 sialidase, Lysosomal sialidase, N-acetyl-alpha-neuraminidase 1
Rabbit Recombinant Monoclonal Neuraminidase antibody. Suitable for WB and reacts with Human samples. Cited in 3 publications.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Neuraminidase sometimes called sialidase functions as an enzyme that cleaves sialic acid residues from glycoproteins and glycolipids. This process is essential for the maturation and release of progeny viruses from infected cells. Enzymatically active neuraminidase proteins weigh about 60 kilodaltons and localize on the surface of influenza viruses. Researchers identify its expression on the viral envelope playing a pivotal role in the viral life cycle. Neuraminidase activity is an important target for drug development against influenza.
Neuraminidase significantly impacts viral virulence and host cell infection. It is part of the functional machinery required for viral particle detachment from the host cell membrane facilitating the spread of infection. Neuraminidase works alongside other viral proteins including hemagglutinin which attaches the virus to the host cell. The neuraminidase function of trimming sialic acids is critical in the ongoing interaction between virus and host.
The influenza lifecycle heavily involves neuraminidase-mediated sialic acid cleavage. This enzyme contributes to pathways by enabling the efficient release of new viral particles enhancing the infectivity of the virus. Neuraminidase operates in concert with hemagglutinin which initially binds the virus to host cells by attaching to the sialic acid residues. This interplay is vital in viral replication pathways which propagate the infection cycle.
Influenza directly relates to neuraminidase as it is a primary means by which the virus spreads within the host. Neuraminidase inhibitors are a class of antiviral drugs that target this protein important for treating and managing influenza infections. Besides influenza research links neuraminidase activity to bacterial infections with some bacterial neuraminidases implicated in the pathogenesis of diseases like pneumonia. The relationship to hemagglutinin in viral influenza highlights the significance of neuraminidase as a target in therapeutic interventions.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Blocking and diluting buffer was 5% NFDM /TBST
All lanes: Western blot - Anti-Neuraminidase antibody [EPR15712] (ab197020) at 1/2000 dilution
Lane 1: HeLa (Human epithelial cells from cervix adenocarcinoma) whole cell lysate at 20 µg
Lane 2: Human fetal liver lysate at 20 µg
All lanes: Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution
Developed using the ECL technique.
Predicted band size: 45 kDa
Observed band size: 45 kDa
Exposure time: 3min
All lanes: Western blot - Anti-Neuraminidase antibody [EPR15712] (ab197020) at 1/10000 dilution
All lanes: HepG2 (Human liver hepatocellular carcinoma) whole cell lysate at 20 µg
All lanes: Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution
Developed using the ECL technique.
Predicted band size: 45 kDa
Observed band size: 45 kDa
Exposure time: 3min
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com